Growth recovery in acquired hypothyroidism presenting with height velocity decreasing

Detalhes bibliográficos
Autor(a) principal: Miranda, Patrícia
Data de Publicação: 2019
Outros Autores: Ferraz, Ana, Dias, Ana Lopes, Serra-Caetano, Joana, Cardoso, Rita, Dinis, Isabel, Mirante, Alice
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://doi.org/10.25754/pjp.2019.14831
Resumo: Introduction: Hypothyroidism is a frequent endocrinopathy in pediatrics. In severe cases, the most prevalent clinical manifestation is the decline in height velocity. The objective of this study was to evaluate height recovery after treatment, in children with primary acquired hypothyroidism associated with decline in linear growth. Methods: Analytical cross-sectional retrospective study. Sample was constituted by patients with primary acquired hypothyroidism and decline in height velocity, followed in a tertiary hospital between 1998 and 2017. Variables studied: age at diagnosis, disease duration, target height and stature before and after treatment. Statistic analysis with SPSSÒ, α=0.05. Results: 14 patients were included (71% females). Mean age at diagnosis was 10±3.5 years and mean follow up duration was 3.9±1.9 years. Mean target height was 162.3±8.4cm (-0.9±0.79 sds). The total stature gain was +0.90±0.56 sds (p<0.001), directly correlated with duration of the levothyroxine therapy (Pearson correlation 0.9, p<0.001). There was a gain of +0.48±0.44 sds (p=0.001), +0.33±0.42 sds (p=0.02) and +0.06±0.17 sds (p=0.263) in the 1st, 2nd and 3rd year, respectively, and the family target height was reached in the 3rd year of treatment. The stature gain was statistically significant regardless of the pubertal stage at diagnosis, but the family target height was reached only in the prepubertal group [final stature -0,6 ± 1,07 sds (target height -0,6 ± 0,69 sds)].   Discussion: Levothyroxine therapy had a positive impact in linear growth and lead to achievement of family target height, despite the severity of hypothyroidism presentation.
id RCAP_40158623da380ee7b1513e7a231ac221
oai_identifier_str oai:ojs.revistas.rcaap.pt:article/14831
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Growth recovery in acquired hypothyroidism presenting with height velocity decreasingGrowth Recovery in Acquired Hypothyroidism Presenting with Height Velocity DecreasingOriginal articlesIntroduction: Hypothyroidism is a frequent endocrinopathy in pediatrics. In severe cases, the most prevalent clinical manifestation is the decline in height velocity. The objective of this study was to evaluate height recovery after treatment, in children with primary acquired hypothyroidism associated with decline in linear growth. Methods: Analytical cross-sectional retrospective study. Sample was constituted by patients with primary acquired hypothyroidism and decline in height velocity, followed in a tertiary hospital between 1998 and 2017. Variables studied: age at diagnosis, disease duration, target height and stature before and after treatment. Statistic analysis with SPSSÒ, α=0.05. Results: 14 patients were included (71% females). Mean age at diagnosis was 10±3.5 years and mean follow up duration was 3.9±1.9 years. Mean target height was 162.3±8.4cm (-0.9±0.79 sds). The total stature gain was +0.90±0.56 sds (p<0.001), directly correlated with duration of the levothyroxine therapy (Pearson correlation 0.9, p<0.001). There was a gain of +0.48±0.44 sds (p=0.001), +0.33±0.42 sds (p=0.02) and +0.06±0.17 sds (p=0.263) in the 1st, 2nd and 3rd year, respectively, and the family target height was reached in the 3rd year of treatment. The stature gain was statistically significant regardless of the pubertal stage at diagnosis, but the family target height was reached only in the prepubertal group [final stature -0,6 ± 1,07 sds (target height -0,6 ± 0,69 sds)].   Discussion: Levothyroxine therapy had a positive impact in linear growth and lead to achievement of family target height, despite the severity of hypothyroidism presentation.Introdução: O hipotiroidismo é uma endocrinopatia frequente em idade pediátrica. Nos casos severos, a desaceleração do crescimento estatural é a manifestação clínica predominante. O objetivo foi avaliar a recuperação estatural após o início da terapêutica, em crianças com hipotiroidismo primário adquirido associado a desaceleração estatural. Metodologia: Estudo retrospetivo descritivo. Amostra constituída por doentes com hipotiroidismo primário adquirido e desaceleração estatural, seguidos em consulta de um Hospital Central, entre 1998 e 2017. Variáveis estudadas: idade de diagnóstico, duração da doença, estatura alvo familiar e estatura antes e após tratamento. Análise estatística em SPSS®, α=0,05. Resultados: Foram incluídos 14 doentes (71% do sexo feminino). A idade média ao diagnóstico foi de 10±3,5 anos e a duração média do seguimento foi de 3,9±1,9 anos. A estatura alvo familiar média foi de 162,3±8,4 cm (-0,9±0,79 sds). Registou-se um ganho total de +0,90±0,56 sds (p<0,001), que se correlacionou diretamente com a duração da terapêutica (correlação de Pearson 0,9, p<0,001). Anualmente houve um ganho de +0,48±0,44 sds (p=0,001), +0,33±0,42 sds (p=0,02) e +0,06±0,17 sds (p=0,263) no 1º, 2º e 3º ano, respetivamente, com recuperação da estatura alvo familiar ao 3º ano de tratamento. O aumento estatural foi estatisticamente significativo, independentemente do estadio pubertário ao diagnóstico, com recuperação do potencial de crescimento apenas no grupo pré-púbere [estatura final -0,6 ± 1,07 sds (estatura alvo familiar -0,6 ± 0,69 sds)]. Discussão: A terapêutica de substituição com levotiroxina teve um impacto positivo na recuperação estatural, permitindo atingir o potencial de crescimento genético, apesar da gravidade à apresentação.Sociedade Portuguesa de Pediatria2019-07-15info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttps://doi.org/10.25754/pjp.2019.14831eng2184-44532184-3333Miranda, PatríciaFerraz, AnaDias, Ana LopesSerra-Caetano, JoanaCardoso, RitaDinis, IsabelMirante, Aliceinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-08-03T02:57:54Zoai:ojs.revistas.rcaap.pt:article/14831Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:25:29.662258Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Growth recovery in acquired hypothyroidism presenting with height velocity decreasing
Growth Recovery in Acquired Hypothyroidism Presenting with Height Velocity Decreasing
title Growth recovery in acquired hypothyroidism presenting with height velocity decreasing
spellingShingle Growth recovery in acquired hypothyroidism presenting with height velocity decreasing
Miranda, Patrícia
Original articles
title_short Growth recovery in acquired hypothyroidism presenting with height velocity decreasing
title_full Growth recovery in acquired hypothyroidism presenting with height velocity decreasing
title_fullStr Growth recovery in acquired hypothyroidism presenting with height velocity decreasing
title_full_unstemmed Growth recovery in acquired hypothyroidism presenting with height velocity decreasing
title_sort Growth recovery in acquired hypothyroidism presenting with height velocity decreasing
author Miranda, Patrícia
author_facet Miranda, Patrícia
Ferraz, Ana
Dias, Ana Lopes
Serra-Caetano, Joana
Cardoso, Rita
Dinis, Isabel
Mirante, Alice
author_role author
author2 Ferraz, Ana
Dias, Ana Lopes
Serra-Caetano, Joana
Cardoso, Rita
Dinis, Isabel
Mirante, Alice
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Miranda, Patrícia
Ferraz, Ana
Dias, Ana Lopes
Serra-Caetano, Joana
Cardoso, Rita
Dinis, Isabel
Mirante, Alice
dc.subject.por.fl_str_mv Original articles
topic Original articles
description Introduction: Hypothyroidism is a frequent endocrinopathy in pediatrics. In severe cases, the most prevalent clinical manifestation is the decline in height velocity. The objective of this study was to evaluate height recovery after treatment, in children with primary acquired hypothyroidism associated with decline in linear growth. Methods: Analytical cross-sectional retrospective study. Sample was constituted by patients with primary acquired hypothyroidism and decline in height velocity, followed in a tertiary hospital between 1998 and 2017. Variables studied: age at diagnosis, disease duration, target height and stature before and after treatment. Statistic analysis with SPSSÒ, α=0.05. Results: 14 patients were included (71% females). Mean age at diagnosis was 10±3.5 years and mean follow up duration was 3.9±1.9 years. Mean target height was 162.3±8.4cm (-0.9±0.79 sds). The total stature gain was +0.90±0.56 sds (p<0.001), directly correlated with duration of the levothyroxine therapy (Pearson correlation 0.9, p<0.001). There was a gain of +0.48±0.44 sds (p=0.001), +0.33±0.42 sds (p=0.02) and +0.06±0.17 sds (p=0.263) in the 1st, 2nd and 3rd year, respectively, and the family target height was reached in the 3rd year of treatment. The stature gain was statistically significant regardless of the pubertal stage at diagnosis, but the family target height was reached only in the prepubertal group [final stature -0,6 ± 1,07 sds (target height -0,6 ± 0,69 sds)].   Discussion: Levothyroxine therapy had a positive impact in linear growth and lead to achievement of family target height, despite the severity of hypothyroidism presentation.
publishDate 2019
dc.date.none.fl_str_mv 2019-07-15
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://doi.org/10.25754/pjp.2019.14831
url https://doi.org/10.25754/pjp.2019.14831
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 2184-4453
2184-3333
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Sociedade Portuguesa de Pediatria
publisher.none.fl_str_mv Sociedade Portuguesa de Pediatria
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799133524279689216